NOTCH1 and acute lymphoblastic leukemia: NRR-targeting antibodies are also capable of recognizing and inhibiting Notch1 receptors bearing “class 1” NRR mutations, but are less effective in inhibiting Notch1 activation in T-ALL cells than GSIs.